Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer

Suppression of androgen receptor (AR) activity in prostate cancer by androgen depletion or direct AR antagonist treatment, although initially effective, leads to incurable castration resistant prostate cancer (CRPC) via compensatory mechanisms including resurgence of AR and AR splice variant (ARV) s...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Res
Main Authors: Thomas, Jeffrey D., Longen, Charles G., Oyer, Halley M., Chen, Nan, Maher, Christina M., Salvino, Joseph M., Kania, Blase, Anderson, Kelsey N., Ostrander, William F., Knudsen, Karen E., Kim, Felix J.
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5462524/
https://ncbi.nlm.nih.gov/pubmed/28235766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-1055
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki